The Signatera test represents a significant shift in how cancer is monitored following initial treatment. Unlike traditional blood tests that look for general protein markers, Signatera is a personalized "liquid biopsy" designed to detect Molecular Residual Disease (MRD). When a patient receives their Signatera test results, the report typically focuses on a single binary outcome: Positive or Negative. However, the implications of these results vary significantly based on the stage of the cancer and the timing of the test.

Immediate Interpretation of Signatera Results

At its core, the Signatera test looks for fragments of circulating tumor DNA (ctDNA) in the bloodstream. Because the test is custom-built based on an individual's unique tumor signature, its results are highly specific to that patient’s disease.

The Meaning of a Positive Result

A positive result indicates that the test has detected circulating tumor DNA in the blood sample. In clinical terms, this means that even if imaging scans like CT or MRI are clear, there are still microscopic traces of cancer present in the body at a molecular level.

For patients with early-stage cancer (Stage I-III), a positive result post-surgery often suggests a very high risk of recurrence. In the absence of further treatment, a positive Signatera result is a strong predictor that the cancer may eventually show up on a traditional scan. In metastatic settings (Stage IV), a positive result is used to track the "tumor burden." A rising level of ctDNA might suggest that a current treatment is losing its effectiveness, while a falling level could indicate that the therapy is working.

The Meaning of a Negative Result

A negative result means that the test did not detect any of the 16 specific tumor-informed mutations in the blood at the time of the draw. This is generally an encouraging sign, suggesting that the treatment has reduced the cancer to levels below the detection limit of the assay.

However, a negative result is not a guarantee that the cancer is gone forever. It simply means no DNA was found in that specific sample. Cancer cells can sometimes "shed" DNA at low levels or intermittently. This is why oncology teams emphasize serial testing—repeated tests over months or years—to ensure that the status remains negative.

The Science of Personalization in MRD Testing

To understand why these results are more sensitive than standard blood tests, it is necessary to look at how Signatera is created. Most liquid biopsies are "one-size-fits-all," looking for common mutations found across many patients. Signatera is "tumor-informed."

The process begins with a tissue sample from the patient’s original tumor (usually from a biopsy or surgical resection) and a baseline blood sample. Genomic sequencing identifies the unique "fingerprint" of the patient’s cancer. Natera, the lab behind the test, then selects 16 specific "clonal" mutations—those that are present in every cancer cell of that specific patient.

By focusing only on these 16 specific mutations, the test avoids "noise" from other genetic variations, such as Clonal Hematopoiesis of Indeterminate Potential (CHIP), which can lead to false positives in non-personalized tests. The sensitivity is remarkable, with a limit of detection (LOD) as low as 0.01% variant allele frequency (VAF). This means the test can find one piece of tumor DNA in a sea of 10,000 healthy DNA fragments.

Clinical Lead Time and the Window of Opportunity

One of the most critical aspects of Signatera test results is the concept of "lead time." This is the period between when the test turns positive and when the cancer becomes visible on a traditional imaging scan (CT, PET, or MRI).

Clinical data across multiple cancer types, including colorectal, breast, lung, and bladder cancer, shows that Signatera can detect molecular recurrence months before imaging.

  • Colorectal Cancer: Average lead time of 8.7 months.
  • Breast Cancer: Average lead time of 9.5 months, with some cases detected up to 2 years early.
  • Lung Cancer: Average lead time of 4.0 months.
  • Bladder Cancer: Average lead time of approximately 2.8 months.

This lead time provides a "window of opportunity." Instead of waiting for a tumor to grow large enough to be seen on a scan (which often means it is harder to treat), a positive Signatera result allows oncologists to consider intervening earlier. This might include starting adjuvant chemotherapy, switching immunotherapy agents, or increasing the frequency of surveillance.

How Results Impact Specific Cancer Types

The utility of a Signatera report depends heavily on the specific type of cancer being monitored.

Muscle Invasive Bladder Cancer (MIBC)

In the context of bladder cancer, Signatera has been validated through landmark studies like IMvigor 011 and CheckMate 274. For patients who have undergone a radical cystectomy, a positive Signatera result post-surgery identifies those who are most likely to benefit from adjuvant immunotherapy.

Data shows that patients who are Signatera-positive and receive immunotherapy have a significantly reduced risk of death or recurrence (a 41% reduction in risk in some cohorts). Conversely, patients who remain "serially negative"—meaning multiple tests over time show no ctDNA—have excellent survival outcomes even without additional adjuvant therapy. This allows some patients to safely avoid the toxicity of unnecessary treatments.

Colorectal Cancer (CRC)

For CRC patients, Signatera is often used after surgery to determine the need for "mop-up" chemotherapy. If the test is positive after surgery, it indicates that microscopic disease remains, and chemotherapy is typically recommended. If the test is negative, the patient might be a candidate for closer observation, potentially sparing them from the side effects of chemotherapy if the risk of recurrence is low.

Breast and Lung Cancers

In breast cancer monitoring, particularly for high-risk subtypes like Triple-Negative Breast Cancer (TNBC) or HER2+, Signatera provides a way to monitor for relapse in the years following initial treatment. Because breast cancer can recur many years later, the high specificity of the 16-mutation panel is vital for long-term surveillance.

Understanding the MTM/mL Metric

When reviewing a Signatera report, patients may notice a quantitative value: MTM/mL (Mean Tumor Molecules per milliliter). This is a measure of the concentration of tumor DNA in the blood.

  • Quantitative Tracking: Unlike a simple yes/no, the MTM/mL value allows doctors to track the "trend" of the disease.
  • Stable or Decreasing Levels: If a patient is on treatment and their MTM/mL value is decreasing, it provides objective evidence that the cancer is responding to the therapy.
  • Increasing Levels: A rising MTM/mL level, even if the patient feels well, can be an early warning sign that the cancer is becoming more active or developing resistance to current drugs.

It is important to note that the absolute number of MTM/mL is less important than the trend over time. A value of 2.5 MTM/mL isn't necessarily "better" or "worse" than 5.0 in isolation; the key is whether that number is moving up or down in subsequent tests.

Practical Considerations: Timeline and Access

Receiving Signatera results is a multi-step process that requires patience, especially during the initial setup.

  1. The First Test (The "Build" Phase): Because the test is personalized, the lab must first sequence the tumor tissue. This initial process takes about 2 to 4 weeks from the time the lab receives both the tissue and the blood sample.
  2. Follow-on Tests (The "Monitoring" Phase): Once the personalized assay is created, subsequent blood draws are much faster. Results typically return within 7 to 10 days after the blood sample reaches the lab.
  3. Frequency of Testing: Most oncologists order the test every 3 months during the first few years of surveillance, though this can vary based on individual risk factors.
  4. Insurance and Medicare: Signatera is covered by Medicare for several indications, including colorectal, breast, ovarian, and muscle-invasive bladder cancer, as well as for monitoring response to immunotherapy in any solid tumor. For patients with private insurance, Natera often provides patient assistance programs to manage out-of-pocket costs.

Navigating the Emotional Impact of Results

Waiting for cancer test results, often called "scanxiety," is a significant burden for patients. Signatera introduces a new layer to this experience.

A positive result can be distressing, especially when a patient feels physically fine and their traditional scans are clear. It is crucial to view a positive result not as a "failure," but as "actionable intelligence." It gives the medical team a head start. On the other hand, while a negative result provides immense relief, it should be viewed as a "snapshot in time." Maintaining the schedule of serial testing is the best way to turn that single negative result into long-term peace of mind.

Frequently Asked Questions

Can I have a false positive with Signatera?

False positives are extremely rare with Signatera because the test is "tumor-informed." It only looks for mutations that were already confirmed to be in your specific tumor. By filtering out CHIP (age-related mutations in blood cells), the test maintains a specificity of over 99%.

What if my Signatera is positive but my CT scan is clear?

This is a common scenario known as "molecular recurrence." It means the cancer is present at a microscopic level but is not yet large enough to be detected by the resolution of a CT scan. Your doctor will use this information to decide whether to start treatment early or increase the frequency of your scans.

Does a negative result mean I am cured?

"Cured" is a word doctors use cautiously. A negative result means no ctDNA was detected today. It is a very positive sign and correlates with a lower risk of recurrence, but continued monitoring is necessary to ensure the cancer does not reappear later.

How do I get the Signatera test?

The test must be ordered by a licensed healthcare provider, typically an oncologist. If you are interested in MRD monitoring, you should ask your doctor if you are a candidate based on your cancer type and stage.

Summary of Key Findings

Understanding Signatera test results is about looking beyond a simple positive or negative label. It is about recognizing the power of personalized genomic monitoring to stay one step ahead of cancer.

  • Personalization is Key: The test is built from your own tumor, making it uniquely sensitive to your specific cancer signature.
  • Positive Results: Indicate the presence of molecular residual disease (MRD) and a higher risk of recurrence, often serving as an early warning months before scans show anything.
  • Negative Results: Suggest that tumor DNA is not detectable, which is an encouraging indicator of treatment success, though serial testing is required for ongoing certainty.
  • The MTM/mL Metric: Provides a quantitative way to track whether the disease burden is increasing or decreasing over time.
  • Clinical Utility: Studies like IMvigor 011 show that these results can directly guide treatment decisions, helping patients receive the right therapy at the right time while avoiding unnecessary toxicity.

By integrating Signatera into regular surveillance, patients and doctors move from a reactive "wait and see" approach to a proactive strategy of molecular management. Always ensure you review the full report with your oncology team to determine the best next steps for your specific clinical situation.